There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and Grifols SA (GRFS – Research Report) with bullish sentiments.
Biogen (BIIB)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen on June 14 and set a price target of $351.00. The company’s shares closed last Friday at $297.48.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $336.26, an 11.9% upside from current levels. In a report issued on June 1, Mizuho Securities also maintained a Buy rating on the stock with a $340.00 price target.
See today’s best-performing stocks on TipRanks >>
Grifols SA (GRFS)
Kepler Capital analyst Pablo de Renteria maintained a Buy rating on Grifols SA on June 15 and set a price target of EUR17.50. The company’s shares closed last Friday at $9.08.
Renteria has an average return of
According to TipRanks.com, Renteria is ranked #7903 out of 8414 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Grifols SA with a $17.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- Sage Therapeutics price target raised to $66 from $61 at BofA
- Biogen Announces Changes to Its Board of Directors
- Biogen price target raised to $350 from $330 at Canaccord
- Here’s Why Biogen Stock (NASDAQ:BIIB) is Trending Higher
- FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
